“Flexner’s Fabulous Formulations!” A Review of Long-Acting Antiretrovirals and Other New Investigational Drugs for HIV Infection


Charles W. Flexner, MD
The Johns Hopkins University School of Medicine


October 11, 2018 - 10:00 AM


October 11, 2018 - 11:15 AM

Add to iCal Calendar


Assessment of Needs

Long-acting antiretroviral formulations have the potential to improve convenience and adherence compared with standard daily oral regimens. This webinar will review new investigational drugs, including long-acting formulations that are in preclinical and clinical development. There will also be a discussion on challenges in using these agents, including managing adverse effects and drug-drug interactions and deciding what to do about long-lasting drug concentrations at the end of a dosing interval that could lead to the emergence of drug resistance. Novel approaches to drug delivery, including implant devices, gastric reservoirs, and transdermal microneedle patches, will also be reviewed. It’s gonna’ be fabulous!

Learning Objectives

Upon completion of this webinar, learners will be able to:

  • List investigational oral antiretroviral drugs in current clinical development
  • List investigational long acting antiretroviral drugs in current clinical development
  • Describe potential advantages and disadvantages of long acting parenteral antiretroviral formulations as compared to oral formulations


Who Should Attend

This advanced webinar is designed for clinical decision makers who are actively involved in HIV care and research.

This activity is also relevant for registered nurses, PharmDs, and other health professionals.

Individual registration is required, even if you are viewing as a group, in order to receive CME credit or a certificate of participation.

Registration closes on Wednesday, October 10, 2018, 4:00 PM (PT).

Certificates will be available after the completion of the evaluation and claim form.

For more information or questions, please contact the registration department at registration“at”iasusa.org or 415-544-9400.

Conflicts of Interest

In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.

The ACCME defines a commercial interest as “any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.”

Disclosure Information

Dr Flexner has served as a consultant to Cipla Pharmaceuticals, Janssen Pharmaceuticals, Merck, Mylan Pharmaceuticals, and ViiV Healthcare, and received research grant support paid to his institution from Gilead Sciences, Inc. (Updated 09/27/18)

Anonymous reviewer has no relevant financial affiliations to disclose. (Updated 10/01/18)

Continuing Education Credits

CME Credits

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The IAS–USA designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credits

Educational Review Systems is an approved approver of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.  Provider # 5-115. This program is approved for 1.25 hours of continuing nursing education.

Educational Review Systems is also approved for nursing continuing education by the state of California, the state of Florida and the District of Columbia.

This program is approved for 1.25 hours of pharmacotherapy credit.

Pharmacy Credits

Accreditation Council for Pharmacy Education logoEducational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is approved for 1.25 hours (0.125 CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
UAN # 0761-9999-18-306-L02-P

Grant Support

This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.

Gilead Sciences, Inc
ViiV Healthcare

Janssen Therapeutics

Frequently Asked Questions

View our list of FAQs about attending a webinar.

Further Questions?
Please contact the registration department at registration“at”iasusa.org or 415-544-9400.